Risk of delays in new product development and failure to meet plans
First written in FY2016. 2 of 3 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2022: 2 of 13 companies on the "Worse" side.
16 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「If new product development does not progress as planned and research and development expenses increase, or if development delays result in a decline in sales,」
The company continues to respond to the risks of delays in new product development, higher research and development expenses and declining sales through efficient development methods and platform design. - FY2021RestatedAnnual report
「If new product development does not progress as planned and research and development expenses increase, or if development delays result in a decline in sales, this could affect the Group's operating results and financial position.」
The company has reconfirmed the risks of delays in new product development, higher research and development expenses and declining sales, along with its response through efficient development methods and the accumulation of expertise. - FY2016First statedAnnual report
「If new product development does not progress as planned, resulting in higher research and development expenses or a decline in sales due to the obsolescence of existing products, or if sales of launched new products fail to reach plan, this could affect the Group's operating results and financial position.」
The company identifies development delays, higher research and development expenses, obsolescence of existing products and new-product sales falling short of plan as risks.